2,872,537 Shares in Astria Therapeutics, Inc. (NASDAQ:ATXS) Bought by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. purchased a new stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 2,872,537 shares of the biotechnology company’s stock, valued at approximately $25,680,000. Astria Therapeutics accounts for about 4.4% of Fcpm Iii Services B.V.’s portfolio, making the stock its 6th largest holding. Fcpm Iii Services B.V. owned 0.05% of Astria Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of Astria Therapeutics in the fourth quarter worth about $41,000. Tower Research Capital LLC TRC grew its stake in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 2,766 shares during the period. BNP Paribas Financial Markets acquired a new stake in Astria Therapeutics during the fourth quarter valued at $50,000. Virtus ETF Advisers LLC purchased a new position in Astria Therapeutics during the fourth quarter worth approximately $65,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of Astria Therapeutics during the 4th quarter valued at approximately $91,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

Shares of NASDAQ ATXS opened at $4.43 on Friday. Astria Therapeutics, Inc. has a 1 year low of $3.56 and a 1 year high of $12.92. The company has a market capitalization of $250.23 million, a P/E ratio of -2.12 and a beta of 0.45. The company has a 50 day simple moving average of $5.26 and a 200-day simple moving average of $7.71.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01. As a group, research analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ATXS. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Cantor Fitzgerald upgraded Astria Therapeutics to a “strong-buy” rating in a research report on Tuesday, April 29th. Finally, JMP Securities started coverage on Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 price target for the company. Five analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics has an average rating of “Buy” and an average target price of $30.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.